Literature DB >> 23926164

Four main virotypes among extended-spectrum-β-lactamase-producing isolates of Escherichia coli O25b:H4-B2-ST131: bacterial, epidemiological, and clinical characteristics.

Jorge Blanco1, Azucena Mora, Rosalia Mamani, Cecilia López, Miguel Blanco, Ghizlane Dahbi, Alexandra Herrera, Juan Marzoa, Val Fernández, Fernando de la Cruz, Luis Martínez-Martínez, María Pilar Alonso, Marie-Hélène Nicolas-Chanoine, James R Johnson, Brian Johnston, Lorena López-Cerero, Alvaro Pascual, Jesús Rodríguez-Baño.   

Abstract

A total of 1,021 extended-spectrum-β-lactamase-producing Escherichia coli (ESBLEC) isolates obtained in 2006 during a Spanish national survey conducted in 44 hospitals were analyzed for the presence of the O25b:H4-B2-ST131 (sequence type 131) clonal group. Overall, 195 (19%) O25b-ST131 isolates were detected, with prevalence rates ranging from 0% to 52% per hospital. Molecular characterization of 130 representative O25b-ST131 isolates showed that 96 (74%) were positive for CTX-M-15, 15 (12%) for CTX-M-14, 9 (7%) for SHV-12, 6 (5%) for CTX-M-9, 5 (4%) for CTX-M-32, and 1 (0.7%) each for CTX-M-3 and the new ESBL enzyme CTX-M-103. The 130 O25b-ST131 isolates exhibited relatively high virulence scores (mean, 14.4 virulence genes). Although the virulence profiles of the O25b-ST131 isolates were fairly homogeneous, they could be classified into four main virotypes based on the presence or absence of four distinctive virulence genes: virotypes A (22%) (afa FM955459 positive, iroN negative, ibeA negative, sat positive or negative), B (31%) (afa FM955459 negative, iroN positive, ibeA negative, sat positive or negative), C (32%) (afa FM955459 negative, iroN negative, ibeA negative, sat positive), and D (13%) (afa FM955459 negative, iroN positive or negative, ibeA positive, sat positive or negative). The four virotypes were also identified in other countries, with virotype C being overrepresented internationally. Correspondingly, an analysis of XbaI macrorestriction profiles revealed four major clusters, which were largely virotype specific. Certain epidemiological and clinical features corresponded with the virotype. Statistically significant virotype-specific associations included, for virotype B, older age and a lower frequency of infection (versus colonization), for virotype C, a higher frequency of infection, and for virotype D, younger age and community-acquired infections. In isolates of the O25b:H4-B2-ST131 clonal group, these findings uniquely define four main virotypes, which are internationally distributed, correspond with pulsed-field gel electrophoresis (PFGE) profiles, and exhibit distinctive clinical-epidemiological associations.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23926164      PMCID: PMC3811668          DOI: 10.1128/JCM.01555-13

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  46 in total

1.  Molecular epidemiology over an 11-year period (2000 to 2010) of extended-spectrum β-lactamase-producing Escherichia coli causing bacteremia in a centralized Canadian region.

Authors:  Gisele Peirano; Akke K van der Bij; Daniel B Gregson; Johann D D Pitout
Journal:  J Clin Microbiol       Date:  2011-12-07       Impact factor: 5.948

Review 2.  Association between antimicrobial resistance and virulence in Escherichia coli.

Authors:  Gabriela Jorge Da Silva; Nuno Mendonça
Journal:  Virulence       Date:  2012-01-01       Impact factor: 5.882

3.  National survey of Escherichia coli causing extraintestinal infections reveals the spread of drug-resistant clonal groups O25b:H4-B2-ST131, O15:H1-D-ST393 and CGA-D-ST69 with high virulence gene content in Spain.

Authors:  Jorge Blanco; Azucena Mora; Rosalia Mamani; Cecilia López; Miguel Blanco; Ghizlane Dahbi; Alexandra Herrera; Jesús E Blanco; María Pilar Alonso; Fernando García-Garrote; Fernando Chaves; María Ángeles Orellana; Luis Martínez-Martínez; Jorge Calvo; Guillem Prats; María Nieves Larrosa; Juan José González-López; Lorena López-Cerero; Jesús Rodríguez-Baño; Alvaro Pascual
Journal:  J Antimicrob Chemother       Date:  2011-06-13       Impact factor: 5.790

Review 4.  Multidrug-resistant extraintestinal pathogenic Escherichia coli of sequence type ST131 in animals and foods.

Authors:  Joanne L Platell; James R Johnson; Rowland N Cobbold; Darren J Trott
Journal:  Vet Microbiol       Date:  2011-05-13       Impact factor: 3.293

5.  Bacteremia caused by extended-spectrum-β-lactamase-producing Escherichia coli sequence type ST131 and non-ST131 clones: comparison of demographic data, clinical features, and mortality.

Authors:  Hsing-Chun Chung; Chung-Hsu Lai; Jiun-Nong Lin; Chun-Kai Huang; Shiou-Haur Liang; Wei-Fang Chen; Yi-Chun Shih; Hsi-Hsun Lin; Jiun-Ling Wang
Journal:  Antimicrob Agents Chemother       Date:  2011-11-28       Impact factor: 5.191

Review 6.  Escherichia coli O25b-ST131: a pandemic, multiresistant, community-associated strain.

Authors:  Benjamin A Rogers; Hanna E Sidjabat; David L Paterson
Journal:  J Antimicrob Chemother       Date:  2010-11-16       Impact factor: 5.790

7.  High-resolution two-locus clonal typing of extraintestinal pathogenic Escherichia coli.

Authors:  Scott J Weissman; James R Johnson; Veronika Tchesnokova; Mariya Billig; Daniel Dykhuizen; Kim Riddell; Peggy Rogers; Xuan Qin; Susan Butler-Wu; Brad T Cookson; Ferric C Fang; Delia Scholes; Sujay Chattopadhyay; Evgeni Sokurenko
Journal:  Appl Environ Microbiol       Date:  2012-01-06       Impact factor: 4.792

8.  Extended-spectrum beta-lactamase-producing Escherichia coli in Spain belong to a large variety of multilocus sequence typing types, including ST10 complex/A, ST23 complex/A and ST131/B2.

Authors:  Jesús Oteo; Karol Diestra; Carlos Juan; Verónica Bautista; Angela Novais; María Pérez-Vázquez; Bartolome Moyá; Elisenda Miró; Teresa M Coque; Antonio Oliver; Rafael Cantón; Ferran Navarro; José Campos
Journal:  Int J Antimicrob Agents       Date:  2009-05-22       Impact factor: 5.283

9.  Insights into a multidrug resistant Escherichia coli pathogen of the globally disseminated ST131 lineage: genome analysis and virulence mechanisms.

Authors:  Makrina Totsika; Scott A Beatson; Sohinee Sarkar; Minh-Duy Phan; Nicola K Petty; Nathan Bachmann; Marek Szubert; Hanna E Sidjabat; David L Paterson; Mathew Upton; Mark A Schembri
Journal:  PLoS One       Date:  2011-10-28       Impact factor: 3.240

10.  Comparison of Escherichia coli ST131 pulsotypes, by epidemiologic traits, 1967-2009.

Authors:  James R Johnson; Marie-Hélène Nicolas-Chanoine; Chitrita DebRoy; Mariana Castanheira; Ari Robicsek; Glen Hansen; Scott Weissman; Carl Urban; Joanne Platell; Darren Trott; George Zhanel; Connie Clabots; Brian D Johnston; Michael A Kuskowski
Journal:  Emerg Infect Dis       Date:  2012-04       Impact factor: 6.883

View more
  40 in total

1.  Characteristics of Escherichia coli sequence type 131 isolates that produce extended-spectrum β-lactamases: global distribution of the H30-Rx sublineage.

Authors:  Gisele Peirano; Akke K van der Bij; Joshua L Freeman; Laurent Poirel; Patrice Nordmann; Michael Costello; Veronika L Tchesnokova; Johann D D Pitout
Journal:  Antimicrob Agents Chemother       Date:  2014-04-21       Impact factor: 5.191

Review 2.  Escherichia coli ST131, an intriguing clonal group.

Authors:  Marie-Hélène Nicolas-Chanoine; Xavier Bertrand; Jean-Yves Madec
Journal:  Clin Microbiol Rev       Date:  2014-07       Impact factor: 26.132

3.  Modulation of Membrane Influx and Efflux in Escherichia coli Sequence Type 131 Has an Impact on Bacterial Motility, Biofilm Formation, and Virulence in a Caenorhabditis elegans Model.

Authors:  Alix Pantel; Catherine Dunyach-Remy; Christelle Ngba Essebe; Jennifer Mesureur; Albert Sotto; Jean-Marie Pagès; Marie-Hélène Nicolas-Chanoine; Jean-Philippe Lavigne
Journal:  Antimicrob Agents Chemother       Date:  2016-04-22       Impact factor: 5.191

4.  Extensive Genetic Commonality among Wildlife, Wastewater, Community, and Nosocomial Isolates of Escherichia coli Sequence Type 131 (H30R1 and H30Rx Subclones) That Carry blaCTX-M-27 or blaCTX-M-15.

Authors:  Ivana Jamborova; Brian D Johnston; Ivo Papousek; Katerina Kachlikova; Lenka Micenkova; Connie Clabots; Anna Skalova; Katerina Chudejova; Monika Dolejska; Ivan Literak; James R Johnson
Journal:  Antimicrob Agents Chemother       Date:  2018-09-24       Impact factor: 5.191

Review 5.  A new clone sweeps clean: the enigmatic emergence of Escherichia coli sequence type 131.

Authors:  Ritu Banerjee; James R Johnson
Journal:  Antimicrob Agents Chemother       Date:  2014-05-27       Impact factor: 5.191

Review 6.  The role of epidemic resistance plasmids and international high-risk clones in the spread of multidrug-resistant Enterobacteriaceae.

Authors:  Amy J Mathers; Gisele Peirano; Johann D D Pitout
Journal:  Clin Microbiol Rev       Date:  2015-07       Impact factor: 26.132

7.  Multidrug-resistant Escherichia coli soft tissue infection investigated with bacterial whole genome sequencing.

Authors:  Ruaridh Buchanan; Nicole Stoesser; Derrick Crook; Ian C J W Bowler
Journal:  BMJ Case Rep       Date:  2014-10-19

8.  Molecular epidemiology of Escherichia coli sequence type 131 and its H30/H30-Rx subclones recovered from extra-intestinal infections: first report of OXA-48 producing ST131 clone from Iran.

Authors:  Z Hojabri; M Mirmohammadkhani; F Kamali; K Ghassemi; S Taghavipour; O Pajand
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-05-27       Impact factor: 3.267

9.  First Report of Prevalence of CTX-M-15-Producing Escherichia coli O25b/ST131 from Iran.

Authors:  Mohammad Hasan Namaei; Masoud Yousefi; Masoud Ziaee; Alireza Salehabadi; Malaknaz Ghannadkafi; Elham Amini; Parvin Askari
Journal:  Microb Drug Resist       Date:  2017-02-16       Impact factor: 3.431

10.  MALDI-TOF mass spectrometry as a tool for the discrimination of high-risk Escherichia coli clones from phylogenetic groups B2 (ST131) and D (ST69, ST405, ST393).

Authors:  Â Novais; C Sousa; J de Dios Caballero; A Fernandez-Olmos; J Lopes; H Ramos; T M Coque; R Cantón; L Peixe
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-03-07       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.